updat fy sale estimate cc report
exh cc report vs consensu
rep in-lin w/compani guidanc
cc report ep estimate
consensu in-lin w/ guidanc exh forecast
fy cc growth cvg mitg rtg vs guidanc
respect diabet vs low
mid-teen growth guidanc maintain rel valuat pt reiter buy
incl /tax
addit fy comment model gm/om excl
rate vs prior
note oper margin excl
optic appear grow howev underli progress partial
obscur fx overal om improv inclus expens
modestli guidanc aid yr/yr posit impact
currenc hedg expens line item
fy estim chang estim sale
cc report exh cc report vs
consensu report in-lin guidanc cc
growth forecast cc growth cvg vs guidanc similar
growth mitg vs guidanc
rtg vs guidanc diabet vs guidanc
roughli flat yr/yr growth model gm/om excl /om incl /tax
rate vs prior
ep estimate prior in-lin consensu exh
thesi valuat risk continu see upsid share price
given view like enjoy organ msd sale growth
compound-annual-growth-rate margin expans per year share buyback
drive hsd ep growth compound-annual-growth-rate given increas cash
access accru recent enact us tax reform increas
focu free cash flow convers peer group averag
hope aggress vis-a-vi high growth earlier stage
acquisit could add spice stori given mdt unquestion
strength clinic trial regulatori commerci execut
continu pg
tr target
compani diversif size tend obscur particip
stand-alone cgm endo-ven renal denerv offset price pressur matur
declin market innov micra procedur optim mazor/o-arm/stealth
spinal fusion also like mdt recent recommit re-messag back innovation-centr
root alter manag incent highlight margin free cash flow expans
well establish emerg market presenc target valu base initi inclus
tyrx diabet outcom risk share unit healthcar buy david macdonald
pt base rel valuat framework regress estim report
forward top-line compound-annual-growth-rate rel forward price-to-earnings med-tech stock incorpor
estim mdt report revenu compound-annual-growth-rate framework ascrib
rel forward price-to-earnings multipl day averag forward multipl ep
month henc arriv price target risk pt includ emerg market
opacity/volatil greater expect matur product market weak failur meet margin
page
exhibit fy revenu varianc vs consensu segment product categori
page
exhibit cont fy revenu varianc vs consensu segment product categori
page
page
exhibit fy revenu varianc vs consensu segment product categori
page
exhibit cont fy revenu varianc vs consensu segment product categori
page
page
incom statementstrh estimatesactualconsensusno ofstrh estimate vs consensu cc oper incom excl incom incl expens ni ex attribut medtron plc
page
period million oper ens incom excl non-oper net incom ex ni ex attribut margin analysisgross margin excl margin incl margin excl margin attribut analysi y/i cc pf pmr incom attribut medtron plc
world largest medic devic compani leadership across major market
compani four busi segment cardiac vascular minim invas technolog
restor therapi diabet headquart dublin ireland
continu see upsid share price given view like enjoy organ msd
sale growth compound-annual-growth-rate margin expans per year share buyback
drive hsd ep growth compound-annual-growth-rate given increas cash access accru
recent enact us tax reform increas focu free cash flow convers
peer group averag hope aggress vis-a-vi high growth
earlier stage acquisit could add spice stori given mdt unquestion strength
clinic trial regulatori commerci execut compani diversif size tend
obscur particip high growth med-tech segment tavr tmvr
spinal disc close loop insulin deliveri stand-alone cgm endo-ven renal denerv
offset price pressur matur declin market innov micra procedur
optim mazor/o-arm/stealth spinal fusion also like mdt recent recommit re-
messag back innovation-centr root alter manag incent highlight
margin free cash flow expans well establish emerg market presenc target
valu base initi inclus tyrx diabet outcom risk share unit healthcar
valuat risk
pt base rel valuat framework regress estim report
forward top-line compound-annual-growth-rate rel forward price-to-earnings med-tech stock incorpor
estim mdt report revenu compound-annual-growth-rate framework ascrib
rel forward price-to-earnings multipl day averag forward multipl ep
month henc arriv price target risk pt includ emerg market
opacity/volatil greater expect matur product market weak failur meet margin
compani mention note
bruce nudel herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
